IFN-γ induced by IL-12 administration prevents diabetes by inhibiting pathogenic IL-17 production in NOD mice

Journal of Autoimmunity

Volumn 38, Issue 1, 2012, Pages 20-28

  Zhang, Jun ^a   Huang, Zhan ^a   Sun, Rui ^a   Tian, Zhigang ^a   Wei, Haiming ^a  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

Author keywords

Dendritic cells; IFN ; Interleukin 12; Interleukin 17; Type 1 diabetes

Indexed keywords

CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; PEPROTECH; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE CONTROL; DISEASE COURSE; DRUG MECHANISM; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH17 CELL;

ANIMALS; CELLS, CULTURED; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; INJECTIONS, INTRAPERITONEAL; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-17; INTERLEUKIN-23; INTERLEUKIN-6; ISLETS OF LANGERHANS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED NOD; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84856669229     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.11.017     Document Type: Article

References (39)

1. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996, 85:291-297.
2. Anderson M.S., Bluestone J.A. The NOD mouse: a model of immune dysregulation. Annu Rev Immunol 2005, 23:447-485.
3. Gallegos A.M., Bevan M.J. Driven to autoimmunity: the nod mouse. Cell 2004, 117:149-151.
4. Li L., Yi Z., Tisch R., Wang B. Immunotherapy of type 1 diabetes. Arch Immunol Ther Exp (Warsz) 2008, 56:227-236.
5. Banchereau J., Briere F., Caux C., Davoust J., Lebecque S., Liu Y.J., et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000, 18:767-811.
6. Jansen A., van Hagen M., Drexhage H.A. Defective maturation and function of antigen-presenting cells in type 1 diabetes. Lancet 1995, 345:491-492.
7. Takahashi K., Honeyman M.C., Harrison L.C. Impaired yield, phenotype, and function of monocyte-derived dendritic cells in humans at risk for insulin-dependent diabetes. JImmunol 1998, 161:2629-2635.
8. Serreze D.V., Gaskins H.R., Leiter E.H. Defects in the differentiation and function of antigen presenting cells in NOD/Lt mice. JImmunol 1993, 150:2534-2543.
9. Jain R., Tartar D.M., Gregg R.K., Divekar R.D., Bell J.J., Lee H.H., et al. Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. JExp Med 2008, 205:207-218.
10. Mori Y., Kodaka T., Kato T., Kanagawa E.M., Kanagawa O. Critical role of IFN-gamma in CFA-mediated protection of NOD mice from diabetes development. Int Immunol 2009, 21:1291-1299.
11. Honkanen J., Nieminen J.K., Gao R., Luopajarvi K., Salo H.M., Ilonen J., et al. IL-17 immunity in human type 1 diabetes. JImmunol 2010, 185:1959-1967.
12. Marwaha A.K., Crome S.Q., Panagiotopoulos C., Berg K.B., Qin H., Ouyang Q., et al. Cutting edge: increased IL-17-secreting T cells in children with new-onset type 1 diabetes. JImmunol 2010, 185:3814-3818.
13. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., et al. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). JImmunol 1996, 156:5-7.
14. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur J Immunol 1996, 26:1641-1646.
15. Hofstetter H.H., Ibrahim S.M., Koczan D., Kruse N., Weishaupt A., Toyka K.V., et al. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005, 237:123-130.
16. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. JImmunol 2006, 177:566-573.
17. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. Adistinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
18. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 2003, 3:133-146.
19. Trinchieri G., Sher A. Cooperation of toll-like receptor signals in innate immune defence. Nat Rev Immunol 2007, 7:179-190.
20. Cui J., Shin T., Kawano T., Sato H., Kondo E., Toura I., et al. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 1997, 278:1623-1626.
21. Tahara H., Zeh H.J., Storkus W.J., Pappo I., Watkins S.C., Gubler U., et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma invivo. Cancer Res 1994, 54:182-189.
22. Eisenring M., vom Berg J., Kristiansen G., Saller E., Becher B. IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46. Nat Immunol 2010, 11:1030-1038.
23. Decken K., Kohler G., Palmer-Lehmann K., Wunderlin A., Mattner F., Magram J., et al. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 1998, 66:4994-5000.
24. Park A.Y., Hondowicz B.D., Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. JImmunol 2000, 165:896-902.
25. Cooper A.M., Magram J., Ferrante J., Orme I.M. Interleukin 12 (IL-12) is crucial to the development of protective immunity in mice intravenously infected with mycobacterium tuberculosis. JExp Med 1997, 186:39-45.
26. Trembleau S., Penna G., Gregori S., Giarratana N., Adorini L. IL-12 administration accelerates autoimmune diabetes in both wild-type and IFN-gamma-deficient nonobese diabetic mice, revealing pathogenic and protective effects of IL-12-induced IFN-gamma. JImmunol 2003, 170:5491-5501.
27. Trembleau S., Penna G., Bosi E., Mortara A., Gately M.K., Adorini L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. JExp Med 1995, 181:817-821.
28. Matsuoka N., Itoh T., Watarai H., Sekine-Kondo E., Nagata N., Okamoto K., et al. High-mobility group box 1 is involved in the initial events of early loss of transplanted islets in mice. JClin Invest 2010, 120:735-743.
29. O'Hara R.M., Henderson S.L., Nagelin A. Prevention of a Th1 disease by a Th1 cytokine: IL-12 and diabetes in NOD mice. Ann N Y Acad Sci 1996, 795:241-249.
30. Kleinschek M.A., Owyang A.M., Joyce-Shaikh B., Langrish C.L., Chen Y., Gorman D.M., et al. IL-25 regulates Th17 function in autoimmune inflammation. JExp Med 2007, 204:161-170.
31. Emamaullee J.A., Davis J., Merani S., Toso C., Elliott J.F., Thiesen A., et al. Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 2009, 58:1302-1311.
32. Goudy K.S., Burkhardt B.R., Wasserfall C., Song S., Campbell-Thompson M.L., Brusko T., et al. Systemic overexpression of IL-10 induces CD4+CD25+ cell populations invivo and ameliorates type 1 diabetes in nonobese diabetic mice in a dose-dependent fashion. JImmunol 2003, 171:2270-2278.
33. Picarella D.E., Kratz A., Li C.B., Ruddle N.H., Flavell R.A. Transgenic tumor necrosis factor (TNF)-alpha production in pancreatic islets leads to insulitis, not diabetes. Distinct patterns of inflammation in TNF-alpha and TNF-beta transgenic mice. JImmunol 1993, 150:4136-4150.
34. Gu D., Arnush M., Sawyer S.P., Sarvetnick N. Transgenic mice expressing IFN-gamma in pancreatic beta-cells are resistant to streptozotocin-induced diabetes. Am J Physiol 1995, 269:E1089-E1094.
35. Falcone M., Sarvetnick N. Cytokines that regulate autoimmune responses. Curr Opin Immunol 1999, 11:670-676.
36. Krakowski M., Abdelmalik R., Mocnik L., Krahl T., Sarvetnick N. Granulocyte macrophage-colony stimulating factor (GM-CSF) recruits immune cells to the pancreas and delays STZ-induced diabetes. JPathol 2002, 196:103-112.
37. Ohnmacht C., Pullner A., King S.B., Drexler I., Meier S., Brocker T., et al. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. JExp Med 2009, 206:549-559.
38. Ueno H., Klechevsky E., Morita R., Aspord C., Cao T., Matsui T., et al. Dendritic cell subsets in health and disease. Immunol Rev 2007, 219:118-142.
39. O'Garra A., Steinman L., Gijbels K. CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 1997, 9:872-883.